February 22, 2017 1:10 AM ET

Pharmaceuticals

Company Overview of Phibro Animal Health Corporation

Company Overview

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also include antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic inte...

Glenpointe Centre East

3rd Floor

Suite 21

300 Frank West Burr Boulevard

Teaneck, NJ 07666

United States

1,300 Employees

Phone:

201-329-7300

Fax:

201-329-7399

Key Executives for Phibro Animal Health Corporation

Chairman, Chief Executive Officer, President and Member of Compensation Committee
Age: 69
Total Annual Compensation: $2.5M
Chief Financial Officer
Age: 67
Total Annual Compensation: $664.7K
Chief Operating Officer
Age: 52
Total Annual Compensation: $652.7K
Compensation as of Fiscal Year 2016.

Phibro Animal Health Corporation Key Developments

Phibro Animal Mulls Acquisitions

Phibro Animal Health Corporation (NasdaqGM:PAHC) intends to pursue acquisitions. "In order that we can buy more reasonably, it causes us to work a lot harder. But we remain interested in growing the business both organically as well as by acquisition," Jack Bendheim, President and Chief Financial Officer, said.

Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on March 22, 2017

On February 6, 2017, Phibro Animal Health Corporation announced the declaration of a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on March 22, 2017, to stockholders of record at the close of business on March 1, 2017.

Phibro Animal Health Corporation Reports Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2016; Provides Earnings Guidance for the Fiscal Year 2017

Phibro Animal Health Corporation reported consolidated earnings results for second quarter and six months ended December 31, 2016. For the quarter, the company reported net sales of $191.6 million against $191.8 million a year ago. Operating income was $22.6 million against $22.6 million a year ago. Income before income taxes was $19.3 million against $16.1 million a year ago. Net income was $13.4 million or $0.34 per basic and diluted share against $30.2 million or $0.75 per diluted share a year ago. The decrease was a result of the factors described above, including an $18.8 million income tax benefit in the prior year period, partially offset by a $3.1 million favorable change in foreign currency (gains) losses, net. EBITDA was $29.6 million against $25.5 million a year ago. Adjusted EBITDA was $31.2 million against $28.4 million a year ago. Adjusted net income was $15.4 million against $14.7 million a year ago. Net cash provided by operating activities was $26.3 million against $8.0 million a year ago. Capital expenditures were $4.7 million against $9.6 million a year ago. Adjusted diluted EPS of $0.39, an increase of $0.02, or 5%. For the six months, the company reported net sales of $379.6 million against $378.9 million a year ago. Operating income was $44.4 million against $44.5 million a year ago. Income before income taxes was $36.9 million against $39.6 million a year ago. Net income was $25.6 million or $0.64 per diluted share against $48.9 million or $1.22 per diluted share a year ago. EBITDA was $57.4 million against $58.2 million a year ago. Adjusted EBITDA was $61.0 million against $56.1 million a year ago. Adjusted net income was $30.0 million against $28.5 million a year ago. Net cash provided by operating activities was $47.7 million against $5.6 million a year ago. Capital expenditures were $10.6 million against $17.7 million a year ago. For the fiscal year 2017, the company expects net sales to be from $750 million to $770 million, adjusted EBITDA to be from $116 million to $120 million, operating income to be from $95 million to $99 million, income before income taxes to be from $78 million to $82 million, net income to be from $55 million to $58 million and net income per diluted share to be from $1.38 to $1.45.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Phibro Animal Health Corporation, please visit www.pahc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.